Azeliragon

Azeliragon (TTP488, PF-04494700) is an orally bioavailable small molecule that inhibits the receptor for advanced glycation endproducts (RAGE), which is an immunoglobulin-like cell surface receptor overexpressed in brain tissues of patients with AD.


Cat. No.: EX-A1834	Purity: >98%

	Chemical structure of Azeliragon

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
250mg	500	In-stock
500mg	800	In-stock
1g	1200	In-stock
2g	2100	In-stock
5g	3900	In-stock
10g	get quote	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	TTP488
Synonyms 2	PF-04494700
CAS No.	603148-36-3
Purity	>98%
Formula	C32H38ClN3O2
Mol Weight	532.116
Color	white to light yellow
State	solid
Solubility	Soluble in DMSO
Shelf Life	>3 years if stored properly
Storage	Powder 4℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Burstein, A H et al. “Development of Azeliragon, an Oral Small Molecule Antagonist of the Receptor for Advanced Glycation Endproducts, for the Potential Slowing of Loss of Cognition in Mild Alzheimer's Disease.” The journal of prevention of Alzheimer's disease vol. 5,2 (2018): 149-154. doi:10.14283/jpad.2018.18 [2]. Burstein AH, et al. Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis. Clin Pharmacol Drug Dev. 2019 May;8(4):426-435. [3]. Bongarzone S, et al. Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective. J Med Chem. 2017 Sep 14;60(17):7213-7232. [4]. Chen Y, et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008 Sep 15;181(6):4272-8.
CoA	CoA of Azeliragon

Smiles:	CCCCC1=NC(=CN1C1=CC=C(OC2=CC=C(Cl)C=C2)C=C1)C1=CC=C(OCCCN(CC)CC)C=C1


		Search